Nightstar Therapeutics (NITE) BidaskScore is downgraded to Sold

Nightstar Therapeutics

The BidaskScore of Nightstar Therapeutics NITENITE shows that the shares of the company are now NITEStrongly Bought Sold by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Sold since March 26.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Nightstar Therapeutics Ltd is a clinical-stage gene therapy company. It is focused on developing and commercializing a pipeline of novel and potentially curative one-time retinal gene therapies for patients suffering from rare inherited retinal diseases. The company´s retinal gene therapy product candidate NSR-REP1 is being developed for the treatment of choroideremia a rare degenerative X-linked genetic retinal disorder primarily affecting males that is caused by a mutation in the CHM gene.

Nightstar Therapeutics

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.